Suda Pharmaceuticals Ltd Stock Australian S.E.
Equities
SUD
AU0000063661
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- AUD | -.--% | -.--% | -.--% |
Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Sales 2022 | 296K 193K | Sales 2023 | 1.45M 950K | Capitalization | 42.5M 27.76M |
---|---|---|---|---|---|
Net income 2022 | -8M -5.23M | Net income 2023 | -10M -6.53M | EV / Sales 2022 | 32 x |
Net cash position 2022 | 5.93M 3.87M | Net cash position 2023 | 5.18M 3.38M | EV / Sales 2023 | 25.7 x |
P/E ratio 2022 |
-1.47
x | P/E ratio 2023 |
-3.49
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 20-01-01 |
Tim Luscombe
DFI | Director of Finance/CFO | - | Nov. 30 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 22-06-30 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 21-11-09 |
Thomas Duthy
CHM | Chairman | - | 23-03-12 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALA Stock
- SUD Stock